SCHEMBL5083458

SCHEMBL5083458

CC(C)(C)OC(=O)N1CCC(CNc2ccc(-c3ccc(S(C)(=O)=O)cc3)cn2)CC1

nearest known ligand 0.60

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 19/20 0.60
PRMT5 O14744 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5077936 0.90 GPR119 (0.63) GPR119
SCHEMBL13690387 0.89 GPR119 (0.59) GPR119
SCHEMBL3986036 0.89 GRIN2B (0.48) GPR119
SCHEMBL3978507 0.86 USP30 (0.47) GPR119
SCHEMBL3983386 0.85 GPR119 (0.56) GPR119
SCHEMBL3980600 0.84 GRIN2B (0.65)
SCHEMBL870008 0.83 GPR119 (0.59) GPR119
SCHEMBL3979867 0.83 KDM4E (0.51) GPR119
SCHEMBL387584 0.83 GPR119 (0.60) GPR119
SCHEMBL3982989 0.82 KDM4E (0.48) GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080103123-A1 New compounds BIOVITRUM (SE) 2008-05-01 US disclosed
US-20080103123-A1 New compounds BIOVITRUM (SE) 2008-05-01 US disclosed
US-20080103123-A1 New compounds BIOVITRUM (SE) 2008-05-01 US disclosed
WO-2008025798-A1 PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS BIOVITRUM AB (PUBL) (SE) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103123-A1 New compounds GPR119, GPR139, GPR180 GPR119 1/4885PRMT5 2334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.